Radical innovation consists of research and development of new assets, whether they are synthetic, herbal medicines, biological, nutraceuticals, or dermocosmetics products. This research line requires a high investment cost and a long research period.

The company has been engaged in radical innovation research for more than 10 years, when it initially opted for phytomedicines and, today, continues to reinforce the importance of the subject by treating it as one of the cornerstones of its Strategic Planning.

All our actions converge on Aché’s goal to become the innovation leader among national pharmaceutical companies and to achieve a global reach.

The Molecular Design and Synthesis Laboratory (LDSM), which was set up to develop innovative therapeutic solutions for unmet medical needs and to support established processes for the renewal and maintenance of product registrations, was expanded at the Guarulhos plant in 2019. This laboratory has already designed 1500 molecules for the company’s different projects, 500 of which are synthesized inhouse and another 1000 by outside partners, which contributes to the inventive advance and scientific production of the Brazilian pharmaceutical industry that is globally relevant. Expansion of the laboratory once more underlines Aché’s commitment to innovation, as well as fully meeting regulatory demands for the protection of our portfolio and the products in the pipeline.

The release of this laboratory enabled Aché, in 2016, to enter the Structural Genomics Consortium (SGC), an international partnership between universities, governments, and pharmaceutical industries to speed up the development of new medicines. The first milestone was the partnership between Aché, another Brazilian pharmaceutical company and Unicamp for the feasibility of a breakthrough research program aiming the development of new cancer and antiinfectious drugs. For the first time in Brazil, the research will be based on the open innovation model, meaning that all knowledge generated (even the validation phase of the biological targets therapeutic potential) will be in public domain.

The Brazilian Biodiversity Prospecting Program, created last December, was possible thanks to the partnership between Aché, the Brazilian Biosciences Laboratory (LNBio) and Phytobios, a company that conducts expeditions to different biomes for the collection of samples and works on prototypes development. LNBio is part of the National Center for Research in Energy and Material (CNPEM), a social organization supervised by the Ministry of Science, Technology, Innovation and Communications (MCTIC).

In the company, innovation is essential and present not only in products and services, but in its broadest form, undergoing our processes, reaching the routine of each employee.